Skip to main content

Table 1 Patient characteristics

From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Variable

Total

%

Mean/median

Range

Age (years)

5.77/5.16

1.23–13.35

 < 10

211

87.6

  

 ≥ 10

30

12.4

  

WBC

76.5/17

0.4–880

 < 50 × 109

161

66.8

  

 ≥ 50 × 109

80

33.2

  

Gender

 Female

103

43.5

  

 Male

134

56.5

  

Down syndrome

 No

224

94.5

  

 Yes

13

5.5

  

NCI risk

 Standard

145

61.2

  

 High

92

38.8

  

Steroid pretreatment

 No

231

97.5

  

 Yes

6

2.5

  

Immunophenotype

 B-cell

196

82.7

  

 T-cell

41

17.3

  

CNS status

 CNS1

185

78.1

  

 CNS2

26

11.0

  

 CNS3

24

10.1

  

 Missing

2

0.8

  

Testes (male only)

 Not involved

131

97.8

  

 Involved

3

2.2

  

Cytogenetic group

 Normal

41

17.3

  

 Hyperdiploidy

64

27.0

  

 Double trisomy (+)

36a

   

 Double trisomy (−)

28a

   

 ETV6/RUNX1

23

9.7

  

 iAMP(21)

5b

   

 t(1;19)

6

2.5

  

 MLLR

9

3.8

  

 Other

81

34.2

  

 Hypodiploidy (< 44)

0

0.0

  

 Not available

9

3.8

  

 Philadelphia

4

1.7

  
  1. aHD double trisomy (+) and (−) were combined into a single hyperdiploidy (HD) group for analysis
  2. biAMP(21) was combined with “Others” group for analysis